Daniel A. Ermann, MD, reviews a large Medicare Fee-for-Service analysis showing zanubrutinib was associated with longer real-world treatment duration, time to next treatment, and overall survival vs acalabrutinib and ibrutinib in older patients with first-line CLL.
ADVERTISEMENT
ADVERTISEMENT
2026 Copyright © News-Matic.com. All Rights Reserved
